| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical composition modulating activity of α7 and/or α4β2 nicotinic acetylcholine receptors, containing a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrocitrate as an active ingredient.EFFECT: using pharmaceutical composition containing a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3,3,1,1]decane dihydrocitrate having high stability and poor moisture absorption.3 cl, 9 dwg, 6 ex |
